Literature DB >> 9305507

Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

S Gauthier1, N Bodick, E Erzigkeit, H Feldman, D S Geldmacher, J Huff, R Mohs, J M Orgogozo, S Rogers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9305507

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN： 0893-0341            Impact factor:   2.703


× No keyword cloud information.
  5 in total

Review 1.  Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment.

Authors:  Abhilash K Desai; George T Grossberg; Dharmesh N Sheth
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.

Authors:  Roy W Jones; Paul McCrone; Chantal Guilhaume
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

3.  [Validation of indicators of the management of cognitive impairment in geriatric assessment units].

Authors:  Isabelle Payot; Judith Latour; Fadi Massoud; Marie-Jeanne Kergoat
Journal:  Can Fam Physician       Date:  2007-11       Impact factor: 3.275

4.  Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch.

Authors:  José L Molinuevo; Lutz Frölich; George T Grossberg; James E Galvin; Jeffrey L Cummings; Tillmann Krahnke; Christine Strohmaier
Journal:  Alzheimers Res Ther       Date:  2015-03-08       Impact factor: 6.982

5.  Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer's disease.

Authors:  John E Harrison
Journal:  Alzheimers Res Ther       Date:  2018-06-29       Impact factor: 6.982
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.